January 15, 2020 06:35 AM EST
FDA+

UK's NICE is­n't con­vinced by Mer­ck­'s Keytru­da in head and neck can­cer

Natalie Grover

Reporter

There may be 33 new cas­es of head and neck can­cer in the Unit­ed King­dom each day, but the re­gion’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times